Advanced Renal Cell Carcinoma Lenvatinib in Combination with Everolimus is approved as a Second-line Therapy

被引：0
|
作者：
Krampe-Scheidler, Anne
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷 / 10期
关键词：
INHIBITOR; E7080;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：666 / 667
页数：2
相关论文
共 50 条
  • [21] Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma
    Ged, Yasser
    Lee, Chung-Han
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (10) : 1049 - 1059
  • [22] Pembrolizumab as second-line therapy for advanced urothelial carcinoma
    Douchet, G.
    ONCOLOGIE, 2017, 19 (5-6) : 205 - 206
  • [23] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    Bellmunt, J.
    de Wit, R.
    Vaughn, D. J.
    Fradet, Y.
    Lee, J. -L.
    Fong, L.
    Vogelzang, N. J.
    Climent, M. A.
    Petrylak, D. P.
    Choueiri, T. K.
    Necchi, A.
    Gerritsen, W.
    Gurney, H.
    Quinn, D. I.
    Culine, S.
    Sternberg, C. N.
    Mai, Y.
    Poehlein, C. H.
    Perini, R. F.
    Bajorin, D. F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11): : 1015 - 1026
  • [24] Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy
    O'Reilly, Aine
    Larkin, James
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (03) : 251 - 262
  • [25] Lenvatinib Combined With Pembrolizumab or Everolimus Lengthens Survival in Advanced Renal Cell Carcinoma
    Motzer, Robert J.
    Choueiri, Toni
    ONCOLOGY-NEW YORK, 2021, 35 (04): : 220 - 222
  • [26] Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma
    Grande, E.
    Glen, H.
    Aller, J.
    Argenziano, G.
    Lamas, M. J.
    Ruszniewski, P.
    Zamorano, J. L.
    Edmonds, K.
    Sarker, S.
    Staehler, M.
    Larkin, J.
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (12) : 1413 - 1426
  • [27] Multiple Myeloma Darzalex®: Now also approved in Second-Line Combination Therapy
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (06) : 384 - 385
  • [28] COMPARING ITC RESULTS FROM LENVATINIB PLUS EVEROLIMUS FOR SECOND LINE TREATMENT OF ADVANCED/METASTATIC RENAL CELL CARCINOMA: CROSSOVER VERSUS NO CROSSOVER
    Tremblay, G.
    Garib, S. A.
    Meir, G.
    McElroy, H. J.
    Guo, M.
    VALUE IN HEALTH, 2017, 20 (09) : A415 - A416
  • [29] Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis
    Pitt, M.
    Crathorne, L.
    Moxham, T.
    Bond, M.
    Hyde, C.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 41 - 46
  • [30] Second-line systemic therapy in metastatic renal-cell carcinoma: A review
    Jain, Rohit K.
    Gandhi, Shipra
    George, Saby
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (11) : 640 - 646
12345